Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Part of story

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 20262 sourcesDrug development

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Other sources for this story

Reuters

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million | Reuters

Featured Stories

CIA Director John Ratcliffe arrives in Moscow aboard US military plane for meetings

Aug 25, 20268 sources